Hanmi Pharmaceutical will launch a multinational Phase IIb trial of its biologic diabetes treatment, LAPS-Exendin4, with the goal of a weekly or monthly dosing regimen. The study will involve approximately 700 patients with type 2 diabetes or obesity and will be conducted at about 150 centers in a dozen different countries, including the U.S., Europe and Korea. The trial is designed to assess safety and efficacy of LAPS-Exendin4, while determining its dose for Phase III trals. The trial is also...